

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces New Results from EMBARK Study of Elevidys in Duchenne Muscular Dystrophy

TOKYO, January 27, 2025 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on January 27 (local time) regarding new results from EMBARK study of delandistrogene moxeparvec, a gene therapy product under development (development code: SRP-9001, overseas product name: Elevidys) for Duchenne muscular dystrophy (DMD).

Please refer to the link below for details of the press release:

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

<https://www.roche.com/media/releases/med-cor-2025-01-27>

###